DEFM14A: OptiNose Stockholders to Vote on Merger Agreement with Paratek Pharmaceuticals

OptiNose, Inc. has scheduled a special meeting for stockholders to vote on the proposed merger agreement with Paratek Pharmaceuticals, Inc., where stockholders will receive $9.00 per share in cash and a contingent value right (CVR) representing the right to receive up to $5.00 in contingent cash payments.

Summary

• OptiNose, Inc. has entered into a merger agreement with Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company.
• The special meeting of stockholders will be held on May 16, 2025, to vote on the adoption of the merger agreement.
• If the merger is approved, OptiNose stockholders will receive $9.00 per share in cash and one contingent value right (CVR) representing the right to receive up to $5.00 in contingent cash payments.
• The CVR payments are contingent on achieving net sales milestones for XHANCE in the United States.
• The first milestone payment of $1.00 per CVR is triggered if XHANCE achieves net sales of $150 million in any calendar year before December 31, 2028.
• The second milestone payment of $4.00 per CVR is triggered if XHANCE achieves net sales of $225 million in any calendar year before December 31, 2029.
• The board of directors of OptiNose unanimously recommends that stockholders vote in favor of the merger agreement.
• The merger is expected to close in the second or third quarter of 2025, pending stockholder and regulatory approvals.
• Paratek estimates the total funds necessary to complete the merger and related transactions will be approximately $355 million.
• Paratek has secured commitment letters for $99.9 million in equity financing and $275 million in debt financing.
• The merger agreement includes provisions for termination fees, with OptiNose potentially owing Paratek $4.5 million under certain circumstances.
• The exchange of Company common stock for the merger consideration will be a taxable transaction for U.S. federal income tax purposes.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. While the deal provides immediate cash value and potential upside, there are risks associated with achieving the CVR milestones and the loss of equity ownership.

Positives

• Stockholders receive immediate cash value of $9.00 per share.
• Potential for additional $5.00 per share via CVRs if sales milestones are met.
• The merger is not contingent on financing.
• The board of directors unanimously supports the merger.

Negatives

• Stockholders will no longer have an equity stake in the combined company.
• CVR payments are not guaranteed and depend on future sales performance.
• The exchange of shares will be a taxable transaction.
• OptiNose will be delisted from Nasdaq.

Risks

• Failure to achieve sales milestones would result in no CVR payments.
• Regulatory approvals may be delayed or impose burdensome conditions.
• Litigation could delay or prevent the merger.
• The company may be required to pay Paratek a termination fee of $4,500,000 under certain circumstances.

Future Outlook

The merger is expected to close in the second or third quarter of 2025, subject to stockholder and regulatory approvals and other customary closing conditions.

Management Comments

• The board of directors has unanimously determined that the merger agreement and the transactions contemplated by the merger agreement and the CVR agreement, including the merger, are fair to, and in the best interests of the Company and its stockholders.

Industry Context

The announcement reflects a trend of consolidation in the pharmaceutical industry, with larger companies acquiring smaller, specialized firms to expand their product portfolios and market reach.

Comparison to Industry Standards

• Comparable transactions in the specialty pharmaceutical sector often involve upfront cash payments combined with contingent value rights (CVRs) tied to specific milestones.
• The fairness of the merger consideration is assessed by financial advisors like Evercore, who compare the deal terms to similar transactions and analyze the target company's financial projections.
• The premium offered in the merger is compared to historical premiums paid in similar deals to determine its attractiveness to stockholders.
• The CVR structure is a common mechanism to bridge valuation gaps and share potential upside with stockholders.

Legal Proceedings

• The Company has received two demand letters from purported stockholders alleging disclosure deficiencies in the preliminary proxy statement.
• The Company believes that the disclosures set forth in the preliminary proxy statement comply with applicable law and that the allegations asserted in the demand letters are without merit.

Stakeholder Impact

• Stockholders will receive $9.00 per share in cash and a contingent value right (CVR) representing the right to receive up to $5.00 in contingent cash payments.
• Employees may experience changes in their roles and responsibilities following the merger.
• Customers and suppliers may see changes in the company's operations and product offerings.

Next Steps

• The Company will hold a special meeting of stockholders on May 16, 2025, to vote on the merger agreement.
• The Company will work to obtain the necessary regulatory approvals.
• If the merger agreement is approved by stockholders and all other conditions are met, the merger is expected to close in the second or third quarter of 2025.

Key Dates

Keywords

merger, OptiNose, Paratek, stockholders, XHANCE, CVR, agreement, pharmaceutical, financing, milestones